12 Most Oversold Healthcare Stocks to Buy Now

Page 3 of 12

10. CRISPR Therapeutics AG (NASDAQ:CRSP)

Year Perf: -34.11%

Analyst Upside: 57.33%

Number of Hedge Fund Holders: 27

Headquartered in Zug, Switzerland, CRISPR Therapeutics AG (NASDAQ:CRSP) develops transformative gene-based medicines for serious diseases through its proprietary CRISPR/Cas9 platform. The CRISPR/Cas9 platform allows precise changes to genomic DNA by employing gene editing technology. The company’s product portfolio spans therapeutic programs across various disease areas, including oncology, rare diseases, regenerative medicine, etc.

CRISPR Therapeutics AG (NASDAQ:CRSP) is focusing on strategically advancing its portfolio of clinical trials across autoimmune, diabetes, oncology, and cardiovascular indications. The FDA approval and launch of CASGEVY, a gene therapy for treating sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older, have created considerable momentum for the company. CRISPR Therapeutics AG (NASDAQ:CRSP) has also received regulatory approval for the drug in various countries across the globe, including Canada, Switzerland, Great Britain, the European Union, and others, with product launches underway. The ongoing launch of the drug is continually gaining momentum, with new cell patient collection initiations expected to grow significantly in 2025. More than 50 authorized treatment centers (ATCs) have been activated globally for CASGEVY.

As of December 31, 2024, it has a strong balance sheet with around $1.9 billion in cash, cash equivalents, and marketable securities. Thus, supported by an approved commercial product, a strong balance sheet, and a rich pipeline, it is in a suitable position to expand its operations in 2025 and beyond.

Page 3 of 12